Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease

Neurology

Volumn 80, Issue 19, 2013, Pages 1754-1761

  Storch, Alexander ^a,b   Wolz, Martin ^a   Beuthien Baumann, Bettina ^a,c   Löhle, Matthias ^a   Herting, Birgit ^a   Schwanebeck, Uta ^a   Oehme, Liane ^a   Van Den Hoff, Jörg ^c   Perick, Maria ^a   Grählert, Xina ^a   Kotzerke, Jörg ^a   Reichmann, Heinz ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; CABERGOLINE; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EFFECTIVE DOPAMINE DISTRIBUTION VOLUME RATIO; FEMALE; HUMAN; MALE; PARAMETERS; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DOPAMINE; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84879073484     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182918c2d     Document Type: Article

References (38)

1. Pifl C, Schingnitz G, Hornykiewicz O. Striatal and nonstriatal neurotransmitter changes in MPTP-parkinsonism in rhesus monkey: the symptomatic versus the asymptomatic condition. Neurochem Int 1992;20(suppl):295S-297S.
2. Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, Tatsch K. Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline. J Nucl Med 2004;45:1694-1697.
3. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000;23:S8-S19.
4. Brotchie J, Fitzer-Attas C. Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology 2009;72:S32-S38.
5. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 1990;13:290-296.
6. Zigmond MJ, Acheson AL, Stachowiak MK, Stricker EM. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch Neurol 1984;41:856-861.
7. Hornykiewicz O. Imbalance of brain monoamines and clinical disorders. Prog Brain Res 1982;55:419-429.
8. Pifl C, Hornykiewicz O. Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys. Neurochem Int 2006;49:519-524.
9. Sossi V, De La Fuente-Fernandez R, Holden JE, et al. Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab 2002;22:232-239.
10. Doudet DJ, Chan GL, Holden JE, et al. 6-[18F]Fluoro-LDOPA PET studies of the turnover of dopamine in MPTPinduced parkinsonism in monkeys. Synapse 1998;29:225-232.
11. Sossi V, De La Fuente-Fernandez R, Holden JE, Schulzer M, Ruth TJ, Stoessl J. Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J Cereb Blood Flow Metab 2004;24:869-876.
12. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000;47:493-503.
13. Oehme L, Perick M, Beuthien-Baumann B, et al. Comparison of dopamine turnover, dopamine influx constant and activity-ratio of striatum and occipital brain with 18FDOPA-Brain-PET in normal controls and patients with Parkinson's disease. Eur J Nucl Med Mol I 2011;38:1550-1559.
14. Sossi V, De La Fuente-Fernandez R, Nandhagopal R, et al. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord 2010;25:2717-2723.
15. De La Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopainduced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004;127:2747-2754.
16. Sossi V, De La Fuente-Fernandez R, Schulzer M, Adams J, Stoessl J. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain 2006;129:1050-1058.
17. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998;44:S175-S188.
18. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S26-S36;discussion S36-S38.
19. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
20. Piercey MF, Camacho-Ochoa M, Smith MW. Functional roles of dopamine-receptor subtypes. Clin Neuropharmacol 1995;18:34-42.
21. Carter AJ, Muller RE. Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol 1991;200:65-72.
22. Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008;2:CD006564.
23. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
24. Fahn S, Elton RL, Committee UD. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, eds. Recent Developments in Parkinson's Disease. Florham Park: Macmillan Healthcare Information; 1987:153-163, 293-304.
25. Patlak CS, Blasberg RG. Graphical evaluation of blood-tobrain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1985;5:584-590.
26. Huotari M, Gogos JA, Karayiorgou M, et al. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci 2002;15:246-256.
27. Persiani S, Sassolas G, Piscitelli G, et al. Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. J Pharm Sci 1994;83:1421-1424.
28. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
29. Contin M, Riva R, Martinelli P, Albani F, Baruzzi A. Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. Eur J Clin Pharmacol 1991;41:463-466.
30. Nutt JG, Woodward WR, Anderson JL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol 1985;18:537-543.
31. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial: The PKDS009 Study Group. Drugs 1998;55(suppl 1):23-30.
32. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-2653.
33. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405.
34. Ragonese P, D'Amelio M, Savettieri G. Implications for estrogens in Parkinson's disease: an epidemiological approach. Ann NY Acad Sci 2006;1089:373-382.
35. Sossi V, Holden JE, De La Fuente-Fernandez R, Ruth TJ, Stoessl AJ. Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant Kocc and the [18F]fluorodopa plasma input uptake rate constant Ki. J Cereb Blood Flow Metab 2003;23:301-309.
36. Sossi V, De La Fuente-Fernandez R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol 2007;62:468-474.
37. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006;59:559-562.
38. Schapira AH, Olanow CW. Rationale for the use of dopamine agonists as neuroprotective agents in Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S149-S157.